Tutti gli studi
Attivo ma non reclutanteFASE2INTERVENTISTICO

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

This study is an extension of previous research into a medicine called GB002 (also known as seralutinib) for a lung condition called Pulmonary Arterial Hypertension (PAH). It's designed to see how the medicine works over a longer period. If you’ve already taken part in an earlier GB002 study for PAH, and your doctors believe you followed the study rules well, you might be able to join this one. This is an "open-label" study, which means everyone involved – both you and your medical team – will know you are receiving the active drug GB002. The goal is to gather more information about its effects and safety over time, building on what was learned in earlier phases of the research.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE2
Sponsor
Gossamer Bio USA, Inc.
Obiettivo di iscrizione
74
Inizio
05 Apr 2021
Completamento stimato
01 Dic 2027

Di cosa tratta questo studio?

You're looking at information about a research study for a condition called Pulmonary Arterial Hypertension (PAH). PAH is a serious condition where the blood vessels in your lungs become narrowed, making it harder for your heart to pump blood through them. This study is focused on a new medicine called GB002, also known as seralutinib.

This particular study is an 'extension study.' This means it's for people who have already taken part in a previous research study looking at GB002 for PAH. The main aim is to understand the long-term effects of this medicine. Researchers want to see how it works over a longer period, including its benefits and any potential side effects when used over months or even years. This kind of long-term data is really important for understanding how a new medicine performs in the real world.

By joining an extension study, you help scientists gather more complete information about GB002. This allows them to build a full picture of the medicine's safety and how well it helps people manage their PAH over time. The results from studies like this are crucial in deciding if new treatments like GB002 can eventually become widely available to help more people with PAH.

Punti chiave

  • This study is for people who have already participated in a GB002 PAH study.
  • It aims to understand the long-term effects of the medicine GB002 for Pulmonary Arterial Hypertension.
  • It's an 'open-label' study, meaning everyone knows you're getting the active drug.
  • You will continue using an inhaler for the study medicine.
  • Your health will be closely monitored by medical professionals.
  • You can withdraw from the study at any point.

Chi può essere idoneo?

To join this study, you first need to have already taken part in an earlier study looking at GB002 for PAH. It’s also important that your doctors believe you followed the rules of that first study carefully.

You'll need to be between 18 and 80 years old. You should also be taking your usual PAH medicines at a steady dose. Before you can join, you'll be asked to read and sign an informed consent form, which explains everything about the study in detail.

There are also some reasons why you might not be able to join. For example, if you have very high or low blood pressure that is causing problems, or if you've recently developed new heart problems on your left side. Having certain serious infections or a history of severe milk allergies could also prevent you from taking part. People who smoke or vape tobacco or marijuana, or have certain substance use disorders, might also not be eligible.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Have I previously taken part in a GB002 study for PAH?
  2. Am I aged between 18 and 80 years old?
  3. Am I currently on stable doses of my usual PAH medications?
  4. Do I have any serious uncontrolled medical conditions or severe allergies, especially to milk?
  5. Do I currently smoke or vape tobacco/marijuana, or have certain substance use disorders?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in this study, you'll continue to receive the study medicine, GB002, using a generic dry powder inhaler. Because this is an extension study, the exact number of visits, tests, and how long you'll be in the study will build on your experience from the previous GB002 study you were in. The aim is to continue monitoring your health, track the effects of the medication, and identify any long-term side effects. You can expect regular check-ups, which may include physical exams, blood tests, and other assessments related to your PAH. Your medical team will explain the full schedule of visits and what each will involve, as it will be tailored to gather long-term safety and effectiveness information.

Rischi e benefici potenziali

Taking part in this study means you'll continue to receive the promising medicine GB002, which could potentially help manage your PAH symptoms for longer. However, like all medicines, GB002 may have side effects, and these will be carefully monitored throughout the study. There's also the chance that the medicine might not work for you, or that unknown side effects could emerge over a longer period. Your health will be closely watched by the study team. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (28)

  • University of California, Davis Medical Center
    Codice postale verificato
    Sacramento, Stati Uniti
  • Medical Corporation
    Codice postale verificato
    Santa Barbara, Stati Uniti
  • Mayo Clinic
    Codice postale verificato
    Jacksonville, Stati Uniti
  • Cleveland Clinic Florida
    Codice postale verificato
    Weston, Stati Uniti
  • University of Kansas Medical Center
    Codice postale verificato
    Kansas City, Stati Uniti
  • Norton Pulmonary Specialists
    Codice postale verificato
    Louisville, Stati Uniti
  • Tufts Medical Center
    Codice postale verificato
    Boston, Stati Uniti
  • University of Nebraska Medical Center
    Codice postale verificato
    Omaha, United States
  • NYU Langone Health
    Codice postale verificato
    New York, Stati Uniti
  • New York Presbyterian Hospital - Weill Cornell Medicine
    Codice postale verificato
    New York, Stati Uniti
  • Centro Medico dell'Università di Rochester
    Codice postale verificato
    Rochester, Stati Uniti
  • The Ohio State University Wexner Medical Center
    Codice postale verificato
    Columbus, Stati Uniti

Domande comuni

What is 'open-label'?

Open-label means that everyone involved – you, your doctor, and the study team – will know that you are receiving the active study medicine, GB002.

Why is this study only for people who were in a previous GB002 study?

This is an 'extension' study. It builds on earlier research to understand how GB002 works over a longer time in people who have already started treatment.

What is Pulmonary Arterial Hypertension (PAH)?

PAH is a condition where the blood vessels in your lungs become narrow, stiff, or blocked, making it harder for blood to flow through them and causing strain on your heart.

Will I stop taking my other PAH medicines?

No, you will generally continue taking your usual PAH medicines at a stable dose alongside the study medicine, GB002.

What if I decide I don't want to continue the study?

You are free to leave the study at any time, for any reason. Your decision will not affect your regular medical care.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.